drugset / Trial / NCT06373133
SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | BP102 | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | SHR-8068 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | SHR-8068 | Monoclonal antibody | 4 mg/kg | Intravenous |